The re-emergence of clinical research into psychedelics as mental health treatment has become a promising development – particularly in light of the current global mental health crisis. However, persistent stigma around psychedelics, regulatory hurdles, and research challenges are a few factors to overcome before psychedelics could be more widely available. In today’s episode, Jen is joined by Vynamic’s Nick Fletcher and Grace Burtonwood to shine light on the opportunities and challenges psychedelics present to the mental health market.
Podcast Tags: healthcare, life sciences, healthcare news, mental health, psychedelics
Source Links:
- WHO Topics: Mental Health
- WHO Fact Sheets: Mental Disorders
- WHO: Global Health Estimates
- Multidisciplinary Association for Psychedelic Studies (MAPS)
- National Institute on Drug Abuse (NIDA)
- Compass Pathways
- BBC – FDA Advisory Committee Vote on MDMA
- FDA Guidance on Clinical Trials with Psychedelic Drugs
- How To Change Your Mind (Michael Pollen)
- European Medicines Agency (EMA)
Panel – Grace Burtonwood, Jen Burke, Nick Fletcher
Research & Production – Everly Petruzzelli, Nick Fletcher
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Listen now
ASH® 2025 roundtable: Turning hematology innovation into real world progress
Insights from ASH® 2025 on hematology innovation, CAR-T, bispecifics, diagnostics, and how connected strategy supports real-world adoption.
Read moreChina’s ascendent role in oncology therapy innovation
China is emerging as a global oncology innovation hub, reshaping clinical development, dealmaking, and advanced therapy sourcing worldwide.
Read moreFrom high hopes to hesitation: Tracking the shifting barriers to alzheimer’s DMT adoption
Why Alzheimer’s DMT uptake remains low: Explore key barriers, diagnostic gaps, and market insights from 783 physicians worldwide.
Read more